Comparing Codex DNA (DNAY) & Its Peers

Codex DNA (NASDAQ:DNAYGet Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare Codex DNA to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codex DNA and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codex DNA 0 0 3 0 3.00
Codex DNA Competitors 320 1322 1824 58 2.46

Codex DNA currently has a consensus price target of $15.86, indicating a potential upside of 277.54%. As a group, “Analytical instruments” companies have a potential upside of 33.61%. Given Codex DNA’s stronger consensus rating and higher possible upside, equities analysts clearly believe Codex DNA is more favorable than its competitors.

Earnings and Valuation

This table compares Codex DNA and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Codex DNA $11.04 million -$38.96 million -1.82
Codex DNA Competitors $1.19 billion $356.47 million -19.74

Codex DNA’s competitors have higher revenue and earnings than Codex DNA. Codex DNA is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

87.6% of Codex DNA shares are owned by institutional investors. Comparatively, 60.0% of shares of all “Analytical instruments” companies are owned by institutional investors. 13.4% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Codex DNA and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Codex DNA -311.52% -46.56% -36.63%
Codex DNA Competitors -232.13% 7.12% -11.00%

Summary

Codex DNA competitors beat Codex DNA on 7 of the 12 factors compared.

About Codex DNA (Get Rating)

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with MarketBeat.com's FREE daily email newsletter.